MNPR
Monopar Therapeutics Inc.Healthcare · $483M market cap
Verdict
We can't put a fair value on MNPR right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow MNPR
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Nov 2, 2026: no open-market purchases, 8 sales worth $505K and 5 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Tsuchimoto Kim R
director · 2026-11-04
Sold
$43K
Tsuchimoto Kim R
director · 2026-11-04
Sold
$71K
Tsuchimoto Kim R
director · 2026-11-04
Sold
$92K
Tsuchimoto Kim R
director · 2026-11-02
Sold
$84K
Anderson Raymond
director · 2026-11-02
Sold
$105K
Other filings
Questions about MNPR
Are insiders buying MNPR?
Since Nov 2, 2026: no open-market purchases, 8 sales worth $505K and 5 other filings (stock awards, tax withholding and similar).
How can I check MNPR's value myself?
Use the free Sticker Price calculator, already filled with MNPR's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →
Similar stocks · Biotechnology
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Nov 4, 2026. How the Payback Price works